[1]叶 路.益赛普联合柳氮磺吡啶治疗强直性脊柱炎的疗效及对血清炎性因子的影响[J].医学信息,2024,37(16):108-111.[doi:10.3969/j.issn.1006-1959.2024.16.024]
　YE Lu.Efficacy of YISAIPU Combined with Sulfasalazine in the Treatment of Ankylosing Spondylitisand its Effect on Serum Inflammatory Factors[J].Journal of Medical Information,2024,37(16):108-111.[doi:10.3969/j.issn.1006-1959.2024.16.024]
点击复制

益赛普联合柳氮磺吡啶治疗强直性脊柱炎的疗效及对血清炎性因子的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
37卷
期数:
2024年16期
页码:
108-111
栏目:
论著
出版日期:
2024-08-15

文章信息/Info

Title:
Efficacy of YISAIPU Combined with Sulfasalazine in the Treatment of Ankylosing Spondylitisand its Effect on Serum Inflammatory Factors
文章编号:
1006-1959（2024）16-0108-04
作者:
叶 路
吉安县人民医院肾内风湿免疫科，江西 吉安 343100
Author(s):
YE Lu
Department of Renal Rheumatology and Immunology,Ji’an County People’s Hospital,Ji’an 343100,Jiangxi,China
关键词:
强直性脊柱炎; 益赛普; 柳氮磺吡啶; 血清炎性因子; 脊柱疼痛; 晨僵症状
Keywords:
Ankylosing spondylitis; YISAIPU; Sulfasalazine; Serum inflammatory factors; Spinal pain; Morning stiffness symptoms
分类号:
R593.23
DOI:
10.3969/j.issn.1006-1959.2024.16.024
文献标志码:
A
摘要:
目的 研究益赛普（rh TNFR:Fc）联合柳氮磺吡啶（SASP）治疗强直性脊柱炎（AS）的疗效及对患者血清炎性因子的影响。方法 纳入2022年1月-2023年6月吉安县人民医院收治的80例AS患者，经随机数字表法分为对照组（40例）与观察组（40例），对照组采用rh TNFR:Fc治疗，观察组在其基础上联合SASP治疗，比较两组临床疗效、症状改善情况（脊柱疼痛程度、晨僵时间）、血清炎性因子[血沉（ESR）、C反应蛋白（CRP）]、预后康复情况[Bath强直性脊柱炎疾病活动指数（BASDAI）、Bath强直性脊柱炎功能指数（BASFI）]。结果 观察组治疗1、3个月的ASAS20达标率均高于对照组（P＜0.05）；两组治疗后脊柱疼痛程度评分下降，晨僵时间缩短，且观察组脊柱疼痛程度评分小于对照组，晨僵时间短于对照组（P＜0.05）；两组治疗后ESR、CRP水平低于治疗前，且观察组ESR、CRP水平低于对照组（P＜0.05）；两组治疗后BASDAI、BASFI评分均低于治疗前，且观察组BASDAI、BASFI评分低于对照组（P＜0.05）。结论 rh TNFR:Fc联合SASP治疗强直性脊柱炎效果肯定，可提高患者临床疗效，缓解其症状及炎性反应，改善预后。
Abstract:
Objective To study the efficacy of YISAIPU (rh TNFR:Fc) combined with sulfasalazine (SASP) in the treatment of ankylosing spondylitis (AS) and its effect on serum inflammatory factors.Methods Eighty AS patients admitted to Ji’an County People’s Hospital from January 2022 to June 2023 were included and divided into control group (40 patients) and observation group (40 patients) by random number table method. The control group was treated with rh TNFR:Fc, and the observation group was treated with SASP on the basis of rh TNFR:Fc. The clinical efficacy, symptom improvement (spinal pain degree, morning stiffness time), serum inflammatory factors [erythrocyte sedimentation rate (ESR), C-reactive protein (CRP)], prognosis and rehabilitation [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI), Bath Ankylosing Spondylitis Functional Index (BASFI)] were compared between the two groups.Results The ASAS20 compliance rate of the observation group at 1 and 3 months of treatment was higher than that of the control group (P<0.05). After treatment, the score of spinal pain in the two groups decreased, and the time of morning stiffness was shortened, while the score of spinal pain in the observation group was lower than that in the control group, and the time of morning stiffness was shorter than that in the control group (P<0.05). The levels of ESR and CRP in the two groups after treatment were lower than those before treatment, and the levels of ESR and CRP in the observation group were lower than those in the control group (P<0.05). After treatment, the BASDAI and BASFI scores of the two groups were lower than those before treatment, and the BASDAI and BASFI scores of the observation group were lower than those of the control group (P<0.05).Conclusion rh TNFR:Fc combined with SASP is effective in the treatment of ankylosing spondylitis, which can improve the clinical efficacy of patients, relieve their symptoms and inflammatory reactions, and improve the prognosis.

参考文献/References:

[1]戴莉萍,杨婷婷,张会昌,等.生物制剂注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白穴位注射治疗强直性脊柱炎42例临床观察[J].风湿病与关节炎,2023,12(7):20-23.[2]胡佳琳,郝喆,杨颖莹,等.注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白对强直性脊柱炎患者血清DKK-1及骨代谢指标的影响[J].中国医院药学杂志,2021,41(8):820-823.[3]王方明,刘敏黎,朱笑夏,等.柳氮磺砒啶联合醋氯芬酸肠溶片对AS患者炎症反应和免疫功能的影响[J].中国免疫学杂志,2023,39(1):139-143.[4]汪洋,马民玉.风湿祛痛胶囊联合柳氮磺吡啶治疗强直性脊柱炎的临床研究[J].现代药物与临床,2020,35(10):2002-2005.[5]白云静,王效影,晋小荣,等.联合重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白治疗活动性强直性脊柱炎继发骨质疏松症的临床效果观察[J].临床误诊误治,2020,33(11):41-46.[6]李晓龙,苏振炎,张益宏,等.注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白联合沙利度胺对强直性脊柱炎患者血清炎性因子的影响[J].颈腰痛杂志,2020,41(3):321-324.[7]刘钧菲,刘翠华,厉洪江,等.白芍总苷胶囊联合注射用重组人Ⅱ型肿瘤坏死因子受体抗体融合蛋白治疗幼年特发性关节炎23例及对T淋巴细胞免疫、Th1/Th2漂移及红细胞沉降率的影响[J].安徽医药,2020,24(2):381-385.[8]李晓昊,韦嵩,陈志煌,等.经筋微创疗法联合柳氮磺嘧啶治疗强直性脊柱炎疗效观察[J].西部中医药,2020,33(5):127-131.[9]白琳.痹证一号联合柳氮磺吡啶对肾虚湿热型强直性脊柱炎的临床疗效[J].山西医药杂志,2020,49(8):1010-1013.[10]冷燕奎,王强,金斌,等.不同肿瘤坏死因子-α拮抗剂治疗强直性脊柱炎的早期疗效及对炎性指标的影响[J].中国临床药学杂志,2019,28(5):333-336.[11]周进,付林,周珍,等.重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白递减联合沙利度胺递增治疗方案干预活动性强直性脊柱炎的1年评价[J].中国组织工程研究,2019,23(35):5664-5669.[12]张卫华,王婷婷,王东梅,等.注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白剂量优化方案对强直性脊柱炎伴髋关节病变患者的影响[J].中国全科医学,2019,22(16):1973-1977.[13]徐辉,陈永平,邓玲,等.不同益赛普给药方案联合柳氮磺吡啶治疗AS的疗效比较[J].西南国防医药,2019,29(4):443-446.[14]戴璐.柳氮磺胺吡啶联合益赛普治疗不同年龄强直性脊柱炎临床效果及对患者生活质量的影响研究[J].陕西医学杂志,2019,48(2):262-265.[15]肖月,唐远娇,张凌燕,等.重组人Ⅱ型肿瘤坏死因子受体抗体融合蛋白治疗银屑病关节炎30例临床分析[J].中国皮肤性病学杂志,2023,37(6):657-662.[16]张艳,王明杰,徐风金.甲氨蝶呤联合托法替布/益赛普/来氟米特和柳氮磺吡啶对难治性类风湿关节炎患者的疗效比较[J].现代免疫学,2023,43(6):507-513.[17]周雪梅,卢祥云,梁宏达,等.注射用重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白联合甲氨蝶呤治疗活动性类风湿关节炎的效果及安全性研究[J].世界临床药物,2023,44(3):258-262.[18]李荣良,秦松林,李卫勇,等.六藤安脊汤联合柳氮磺吡啶治疗活动期肾虚瘀阻型强直性脊柱炎临床研究[J].山东中医杂志,2023,42(3):239-243.[19]张诺,郭明蔚,陈桂武,等.益赛普联合柳氮磺吡啶治疗强直性脊柱炎疗效及miR-29a、miR-146a的变化[J].分子诊断与治疗杂志,2020,12(5):587-591.[20]庞琳烜,朱平,李治琴,等.托法替布联合柳氮磺吡啶治疗类风湿关节炎的临床研究[J].现代药物与临床,2022,37(11):2574-2577.

相似文献/References:

[1]朱晓波,常 泰.强直性脊柱炎髋关节受累磁共振横断面扫描与 冠状面扫描的对比分析[J].医学信息,2018,31(16):186.[doi:10.3969/j.issn.1006-1959.2018.16.060]
　ZHU Xiao-bo,CHANG Tai.Comparative Analysis of Magnetic Resonance Cross-sectional Scan and Coronal Scan in Hip Joint of Ankylosing Spondylitis[J].Journal of Medical Information,2018,31(16):186.[doi:10.3969/j.issn.1006-1959.2018.16.060]
[2]刘军莲,戴 娜,杨 迎,等.全脊柱MRI对强直性脊柱炎急性炎症的诊断价值[J].医学信息,2019,32(16):167.[doi:10.3969/j.issn.1006-1959.2019.16.057]
　LIU Jun-lian,DAI Na,YANG Ying,et al.Diagnostic Value of Total Spine MRI in Acute Inflammation of Ankylosing Spondylitis[J].Journal of Medical Information,2019,32(16):167.[doi:10.3969/j.issn.1006-1959.2019.16.057]
[3]翁於欢,王璐颖,郑 勇,等.强直性脊柱炎中医证候分布研究[J].医学信息,2020,33(01):151.[doi:10.3969/j.issn.1006-1959.2020.01.049]
　WENG Yu-huan,WANG Lu-ying,ZHENG Yong,et al.Study on TCM Syndrome Distribution of Ankylosing Spondylitis[J].Journal of Medical Information,2020,33(16):151.[doi:10.3969/j.issn.1006-1959.2020.01.049]
[4]陈王曼琍,施春香.Orem自理理论护理对中西医结合治疗强直性脊柱炎的疗效研究[J].医学信息,2020,33(11):182.[doi:10.3969/j.issn.1006-1959.2020.11.060]
　CHEN Man-li,SHI Chun-xiang.Study on the Curative Effect of Orem Self-care Theory Nursing Treatment of Ankylosing Spondylitis with Integrated Traditional Chinese and Western Medicine[J].Journal of Medical Information,2020,33(16):182.[doi:10.3969/j.issn.1006-1959.2020.11.060]
[5]黄少辉,李 渊,李淑婧,等.重组人Ⅱ型肿瘤坏死因子受体-抗体融合蛋白逐步减量维持治疗强直性脊柱炎的效果[J].医学信息,2021,34(02):152.[doi:10.3969/j.issn.1006-1959.2021.02.042]
　HUANG Shao-hui,LI Yuan,LI Shu-jing,et al.Effect of Recombinant Human Type II Tumor Necrosis Factor Receptor-antibody Fusion Protein Reduction on the Treatment of Ankylosing Spondylitis[J].Journal of Medical Information,2021,34(16):152.[doi:10.3969/j.issn.1006-1959.2021.02.042]
[6]张 伟.艾拉莫德联合塞来昔布治疗强直性脊柱炎的疗效[J].医学信息,2022,35(15):114.[doi:10.3969/j.issn.1006-1959.2022.15.026]
　ZHANG Wei.Efficacy of Iguratimod Combined with Celecoxib in the Treatment of Ankylosing Spondylitis[J].Journal of Medical Information,2022,35(16):114.[doi:10.3969/j.issn.1006-1959.2022.15.026]
[7]薛三宝.MRI诊断强直性脊柱炎骶髂关节病变的影像学价值[J].医学信息,2022,35(22):142.[doi:10.3969/j.issn.1006-1959.2022.22.034]
　XUE San-bao.Imaging Value of MRI in Diagnosis of Sacroiliac Joint Lesions in Ankylosing Spondylitis[J].Journal of Medical Information,2022,35(16):142.[doi:10.3969/j.issn.1006-1959.2022.22.034]

更新日期/Last Update: 1900-01-01